Patents by Inventor Robert C. A. Frederickson

Robert C. A. Frederickson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100087728
    Abstract: Methods and systems for identifying and spatially localizing tissues having certain physiological properties or producing certain biological responses, such as the sensation of pain, in response to the application of intense focused ultrasound (acoustic probing or palpation) are provided. In some embodiments, targeted acoustic probing may be guided or visualized using imaging techniques such as ultrasound imaging or other types of non-invasive imaging techniques.
    Type: Application
    Filed: September 18, 2009
    Publication date: April 8, 2010
    Applicants: PHYSIOSONICS, INC., UNIVERSITY OF WASHINGTON
    Inventors: Jeffrey G. JARVIK, Pierre D. MOURAD, Michel KLIOT, Robert C. A. FREDERICKSON
  • Publication number: 20100081893
    Abstract: Methods and systems for identifying and spatially localizing tissues having certain physiological properties or producing certain biological responses, such as the sensation of pain, in response to the application of intense focused ultrasound (acoustic probing or palpation) are provided. In some embodiments, targeted acoustic probing may be guided or visualized using imaging techniques such as ultrasound imaging or other types of non-invasive imaging techniques.
    Type: Application
    Filed: September 18, 2009
    Publication date: April 1, 2010
    Applicants: PHYSIOSONICS, INC., UNIVERSITY OF WASHINGTON
    Inventors: Jeffrey G. JARVIK, Pierre D. MOURAD, Michel KLIOT, Robert C. A. FREDERICKSON
  • Patent number: 7547283
    Abstract: Systems and methods for determining ICP based on parameters that can be measured using non-invasive or minimally invasive techniques are provided, wherein a non-linear relationship is used to determine ICP based on one or more variable inputs. The first variable input relates to one or more properties of a cranial blood vessel and/or blood flow, such as acoustic backscatter from an acoustic transducer having a focus trained on a cranial blood vessel, flow velocity in a cranial blood vessel, and the like. Additional variables, such as arterial blood pressure (ABP), may be used in combination with a first variable input relating to one or more properties of a cranial blood vessel, such as flow velocity of the middle cerebral artery (MCA) to derive ICP using a non-linear relationship.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: June 16, 2009
    Assignee: PhysioSonics, Inc.
    Inventors: Pierre D. Mourad, Brandt Mohr, Michel Kliot, Robert C. A. Frederickson
  • Patent number: 6756362
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: June 29, 2004
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 6417173
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: July 9, 2002
    Assignee: Gliatech, Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 6127348
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: October 3, 2000
    Assignee: Gliatech, Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 6083930
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 4, 2000
    Assignee: Gliatech Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson
  • Patent number: 5994325
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 30, 1999
    Assignee: Gliatech Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 5705178
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used. In a more preferred embodiment, the average molecular weight is about 40,000 to 500,000 Daltons. The present invention further provides compositions and methods to inhibit glial cell invasion, detrimental bone growth and neurite outgrowth. In a preferred embodiment, the inhibitory compositions further comprise an adhesive protein.
    Type: Grant
    Filed: December 8, 1993
    Date of Patent: January 6, 1998
    Assignee: Gliatech, Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 5705177
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: July 26, 1994
    Date of Patent: January 6, 1998
    Assignee: Gliatech Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 5605938
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that he effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: May 31, 1991
    Date of Patent: February 25, 1997
    Assignee: Gliatech, Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 4430327
    Abstract: A method is described for preventing or minimizing the effects of a drug on an embryo or a fetus by placental transport while alleviating pain and anxiety of the pregnant female by administering a pharmaceutically effective amount of a compound of the formulaH-L-Tyr-D-Ala-Gly-L-Phe-L-(N-CH.sub.3)Met-NH.sub.2or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 18, 1982
    Date of Patent: February 7, 1984
    Assignee: Eli Lilly and Company
    Inventor: Robert C. A. Frederickson
  • Patent number: 4331593
    Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D, when applicable, define the chirality;R.sub.1 and R.sub.2 independently are hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.3 is C.sub.1 -C.sub.4 primary or secondary alkyl or --CH.sub.2 CH.sub.2 --S--CH.sub.3 ;R.sub.4 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.5 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;Y is hydrogen or acetyl; andZ is ##STR2## --CH.sub.2 OH, or --CN; subject to the limitation that no more than one of R.sub.4 and R.sub.5 is C.sub.1 -C.sub.3 primary alkyl; are useful analgesic agents.
    Type: Grant
    Filed: October 31, 1980
    Date of Patent: May 25, 1982
    Inventors: Edward L. Smithwick, Jr., Robert C. A. Frederickson, Robert T. Shuman
  • Patent number: 4322342
    Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which:L and D, when applicable, define the chirality;R.sub.1 is hydrogen, C.sub.1 -C.sub.3 primary alkyl, or allyl;R.sub.2 is hydrogen or C.sub.1 -C.sub.3 primary alkyl, subject to the limitation that when R.sub.1 is allyl, R.sub.2 is hydrogen;R.sub.3 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.4 is C.sub.1 -C.sub.4 primary or secondary alkyl;R.sub.5 is hydrogen or C.sub.1 -C.sub.4 primary or secondary alkyl;R.sub.6 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.7 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;Y is hydrogen or acetyl;Z is hydrogen or ##STR2## in which R.sub.8 is C.sub.1 14 C.sub.3 alkyl or hydrogen; and W is isopropyl, --VR.sub.9, or --CH.sub.2 --X--CH.sub.3, in which V is O or S, R.sub.9 is C.sub.1 -C.sub.4 alkyl or aralkyl, and X is O, S, or --CH.sub.2 --, subject to the limitation that, when W is isopropyl, R.sub.7 is C.sub.1 -C.sub.
    Type: Grant
    Filed: October 31, 1980
    Date of Patent: March 30, 1982
    Assignee: Eli Lilly and Company
    Inventors: Edward L. Smithwick, Jr., Robert C. A. Frederickson, Robert T. Shuman
  • Patent number: 4264491
    Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D, when applicable, define the chirality;R.sub.1 and R.sub.2 independently are hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.3 is C.sub.1 -C.sub.4 primary or secondary alkyl or --CH.sub.2 CH.sub.2 --S--CH.sub.3 ;R.sub.4 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.5 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;Y is hydrogen or acetyl; andZ is ##STR2## --CH.sub.2 OH, or --CN; subject to the limitation that no more than one of R.sub.4 and R.sub.5 is C.sub.1 -C.sub.3 primary alkyl; are useful analgesic agents.
    Type: Grant
    Filed: October 3, 1977
    Date of Patent: April 28, 1981
    Assignee: Eli Lilly and Company
    Inventors: Edward L. Smithwick, Jr., Robert C. A. Frederickson, Robert T. Shuman
  • Patent number: 4259234
    Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D, when applicable, define the chirality;R.sub.1 is hydrogen, C.sub.1 -C.sub.3 primary alkyl, or allyl;R.sub.2 is hydrogen or C.sub.1 -C.sub.3 primary alkyl, subject to the limitation that when R.sub.1 is allyl, R.sub.2 is hydrogen;R.sub.3 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.4 is C.sub.1 -C.sub.4 primary or secondary alkyl;R.sub.5 is hydrogen or C.sub.1 -C.sub.4 primary or secondary alkyl;R.sub.6 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.7 is hydrogen or C.sub.1 -C.sub.3 primary alkyl;Y is hydrogen or acetyl;Z is hydrogen of ##STR2## in which R.sub.8 is C.sub.1 -C.sub.3 alkyl or hydrogen; and W is isopropyl, --VR.sub.9, or --CH.sub.2 --X--CH.sub.3, in which V is O or S, R.sub.9 is C.sub.1 -C.sub.4 alkyl or aralkyl, and X is O, S, or --CH.sub.2 --, subject to the limitation that, when W is isopropyl, R.sub.7 is C.sub.1 -C.sub.
    Type: Grant
    Filed: June 20, 1977
    Date of Patent: March 31, 1981
    Assignee: Eli Lilly and Company
    Inventors: Edward L. Smithwick, Jr., Robert C. A. Frederickson, Robert T. Shuman
  • Patent number: 4199499
    Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D define the chirality;R.sub.1 and R.sub.2 independently are hydrogen or C.sub.1 -C.sub.3 primary alkyl;R.sub.3 is C.sub.1 -C.sub.4 primary or secondary alkyl, C.sub.1 -C.sub.2 hydroxyalkyl, or --CH.sub.2 CH.sub.2 --U--CH.sub.3, in which U is O or S;R.sub.4 is C.sub.1 -C.sub.3 primary alkyl;Y is hydrogen or acetyl;Z is --CH.sub.2 OH or ##STR2## in which R.sub.5 is C.sub.1 -C.sub.3 alkyl or hydrogen; and W is isopropyl, --VR.sub.6, or --CH.sub.2 --X--CH.sub.3, in which V is O or S, R.sub.6 is C.sub.1 -C.sub.4 alkyl or aralkyl, and X is O, S, or CH.sub.2 --; are useful analgesic agents.
    Type: Grant
    Filed: August 24, 1978
    Date of Patent: April 22, 1980
    Assignee: Eli Lilly and Company
    Inventors: Edward L. Smithwick, Jr., Robert C. A. Frederickson, Robert T. Shuman
  • Patent number: 4085705
    Abstract: A ventilated animal cage system is provided in which a plurality of animal cages are removably suspended on shelves of a portable rack. Each shelf is hollow to form an air duct that is in communication with the cages suspended therefrom, thus minimizing the possibility of cross-contamination between animals in the cages and personnel in the laboratory room.
    Type: Grant
    Filed: September 17, 1976
    Date of Patent: April 25, 1978
    Assignee: Eli Lilly and Company
    Inventors: Thomas M. Gland, Robert C. A. Frederickson